Сувардио

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Сувардио

Quick Facts

Property Description
Active ingredient Rosuvastatin (as the calcium salt)
Form Oral film-coated tablet
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
General purpose Management of hyperlipidemia and modification of the lipid profile
Origin Synthetic lipid-lowering agent

Сувардио: Active Ingredient and Pharmacological Class

Сувардио is a prescription-only medication whose active component is the synthetic lipid-lowering agent Rosuvastatin (typically provided as the calcium salt). This drug is explicitly classified as an HMG-CoA Reductase Inhibitor, placing it firmly within the widely recognized statin class of medicines. This classification defines the drug's mechanism and its role in treating lipid disorders.

This classification as an HMG-CoA Reductase Inhibitor is central to its function. Rosuvastatin is designed to work internally by selectively targeting and blocking the HMG-CoA reductase enzyme in the liver, which plays the rate-limiting role in cholesterol production (hepatic sterol synthesis). Rosuvastatin is further recognized as a hydrophilic statin, a chemical attribute that supports its highly targeted distribution primarily to the liver, thereby enhancing its therapeutic effect in the central organ of cholesterol metabolism. This targeted action is recognized for its potency in addressing high LDL-C levels.


Form, Type, and General Function

Сувардио is supplied as an oral film-coated tablet, a standardized solid dosage form designed for ingestion via the oral route, and it is manufactured as a single-ingredient product. The general function of this type of medication is to regulate high blood fat levels and support long-term vascular health, often used in cases of diagnosed hyperlipidemia.

The therapeutic purpose stems directly from the enzyme inhibition: the drug achieves a profound reduction of LDL-C (Low-Density Lipoprotein Cholesterol or "bad" cholesterol), alongside a beneficial increase in HDL-C and a reduction of Triglycerides (TG). The primary intended function of Rosuvastatin is to reduce elevated total cholesterol, LDL-C, and triglycerides. This capability supports strategies designed to slow the progression of fatty deposits (atherosclerosis), thus serving a critical preventative role against cardiovascular disease in patients with diagnosed dyslipidemia.

Regulatory References

  1. NIH StatPearls

What side effects are possible with Сувардио?

Possible Side Effects and Safety Information

The safety profile of Rosuvastatin (Сувардио) is characterized by adverse reactions that are classified by frequency and system-organ class, as documented in official regulatory labeling. These classifications establish the expected incidence of effects, ranging from very common to those of unknown frequency, derived from clinical trials and postmarketing experience .

Frequency and System-Organ Classes

The most commonly documented adverse reactions (classified as Common in regulatory documents) include myalgia (muscle pain), headache, constipation, nausea, abdominal pain, and asthenia (weakness). Uncommon reactions include pruritus, rash, and urticaria. Adverse events are formally categorized by the affected system, such as Musculoskeletal and connective tissue disorders, Nervous system disorders, and Hepatobiliary disorders.

Serious Adverse Reactions and Key Constraints

The official labeling documents rare but serious adverse reactions, notably myopathy and rhabdomyolysis, a severe muscle breakdown that can lead to renal failure. Other serious effects include rare reports of hepatic failure and severe hypersensitivity reactions such as angioedema. The risk of musculoskeletal effects may increase with higher doses (e.g., 40 mg dose) and in certain populations.

Official safety restrictions state that Rosuvastatin is contraindicated in patients with active liver disease, during pregnancy, and during lactation. Individuals of Asian ethnicity and those with severe renal impairment are documented to have increased systemic exposure, which is an important safety consideration explicitly stated in prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

A suspected overdose of Сувардио (Rosuvastatin) requires immediate medical attention. Government regulatory documentation mandates that individuals must get medical help right away or contact a certified Poison Control expert.

The official regulatory profile indicates that the most serious risks associated with high exposure are severe manifestations of toxicity, including myopathy (muscle weakness, pain) and findings of potential hepatic injury (liver damage), which may be confirmed by elevated serum transaminases and Creatine Kinase (CK) levels. The most severe outcomes documented in the context of high exposure are Rhabdomyolysis (severe muscle breakdown) and Acute Renal Failure.

Since no specific antidote is known for Rosuvastatin overdose, treatment is constrained to providing symptomatic and general supportive measures. The drug is highly protein-bound, meaning hemodialysis is not expected to be an effective removal procedure. Hospital management requires continuous monitoring of liver and kidney function and CK levels to assess the progression of tissue damage.

Therapeutic Uses of Сувардио

What Сувардио Treats: Main Uses and Benefits

Сувардио is a medication relevant for managing conditions characterized by systemic imbalance in blood fats, which are considered relevant risk factors for long-term vascular disease. This therapy helps lower harmful fats like LDL cholesterol and triglycerides, while supporting an increase in High-Density Lipoprotein Cholesterol (HDL-C).

Targeting Elevated Blood Lipids and Dyslipidemia

Сувардио is commonly used to help manage significant and chronic elevations in blood fats, defining conditions such as mixed dyslipidemia and the inherited condition Familial Hypercholesterolemia. The therapeutic benefit is the modification of these abnormal lipid patterns, including raising High-Density Lipoprotein Cholesterol (HDL-C), which is commonly used when supportive symptom management is appropriate in situations where high cholesterol may not be sufficiently managed by diet and lifestyle changes alone.

Reducing the Risk of Major Cardiovascular Events

The medication provides long-term preventative support and is applied in situations involving the progressive development of atherosclerosis (plaque build-up) within the arteries. By assisting with managing harmful lipids, Сувардио is relevant for easing the overall symptom burden as it may assist with reducing the probability of major vascular events, such as a heart attack or a stroke, in individuals identified as high-risk.

Quick Fact: Relief for Lipid Imbalance
Primary Focus: Managing elevated LDL-C and triglycerides.
Key Benefit: Provides long-term preventative support against major vascular events.
Applicable Contexts: Chronic dyslipidemia; high cardiovascular risk; inherited high cholesterol (FH).

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Сувардио (Rosuvastatin) is strictly defined by regulatory guidelines based on age, physiological status, and underlying conditions.

Population Eligibility Status
Adults (General) Approved
Pediatric Patients Approved (Ages 7/8–17 for specific types of FH)
Pregnant or Breastfeeding Women Contraindicated

Absolute Contraindications

The medicine must not be used in patients with active liver disease or known hypersensitivity to any component. Use is strictly contraindicated during pregnancy and lactation, due to the potential for fetal harm. Additional prohibitions include existing myopathy and concurrent treatment with cyclosporine, as stated in some regulatory labels.

Conditional Use and Restrictions

Eligibility is conditional on a patient's organ function. The drug is contraindicated for all doses in patients with severe renal impairment (EU/EMA label), and the highest 40 mg dose is restricted in those with moderate renal impairment. Furthermore, the 40 mg dose is contraindicated in patients with predisposing factors for muscle problems, such as uncontrolled hypothyroidism. Due to observed systemic exposure, a lower starting dose is often advised for patients of Asian descent and those over 65 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interaction patterns for Rosuvastatin (Сувардио), as described in authoritative government drug labels.


Interaction Classifications and Restrictions

Rosuvastatin's interaction profile is defined by its role as a substrate for specific transport proteins. Co-administration with inhibitors of Organic Anion Transporting Polypeptides (OATP) and Breast Cancer Resistance Protein (BCRP), such as Ciclosporin and certain antiviral combinations, results in a documented increase in rosuvastatin plasma concentration.

Formal restrictions exist for these combinations. For example, use with Ciclosporin is a documented contraindication in some regions, or requires the rosuvastatin dose to not exceed 5 mg once daily. Additionally, official labels mandate that the 40 mg rosuvastatin dose is contraindicated for patients with moderate renal impairment.

Interaction Type Interacting Substance/Condition
Pharmacodynamic Risk Fibrates, high-dose Niacin, Colchicine
Timing Requirement Aluminum and Magnesium Hydroxide Antacids (must be taken 2 hours apart)
Monitoring Requirement Coumarin Anticoagulants (necessitates frequent INR monitoring)

These constraints ensure compliance with regulatory standards for managing drug exposure. The regulatory profile notes that heavy alcohol consumption may increase the documented risk of liver damage.

Mechanism of Action

How Сувардио Works

The mechanism of Сувардио (Rosuvastatin) is a multi-step pharmacological cascade initiated in the liver, which modulates specific biological pathways that influence lipid metabolism and vascular signaling.


Inhibition of Endogenous Cholesterol Synthesis

Rosuvastatin is a competitive inhibitor of the HMG-CoA Reductase enzyme, which catalyzes the rate-limiting step in the liver’s mevalonate pathway. By selectively blocking this enzyme in hepatocytes, the drug reduces the body's internal synthesis of cholesterol. This mechanistic action results in an intracellular cholesterol deficit, which then triggers the next phase of the drug’s physiological effect.


⬆️ Upregulation of LDL-C Receptor Clearance

In response to the cholesterol deficit, liver cells activate regulatory proteins (SREBP) that lead to an upregulation of Hepatic LDL Receptors (LDL-R) on the cell surface. This increased receptor expression enhances the liver’s capacity to capture and internalize Low-Density Lipoprotein Cholesterol (LDL-C) particles directly from the bloodstream. The consequence is a reduction in the concentration of circulating LDL-C in the plasma.


️ Non-Lipid Vascular Pathway Modulation

The inhibition of the mevalonate pathway also reduces the downstream production of isoprenoids, which are essential for activating specific signaling G-proteins within the vascular wall. This mechanistic consequence modulates anti-inflammatory pathways in the blood vessels and influences the function of the endothelial lining. This activity is correlated with the modulation of systemic vascular processes.

Dosage and Administration Information

How to Use Сувардио: Official Administration Guidelines

Сувардио (Rosuvastatin) is administered as an oral film-coated tablet, and its usage is according to a structured protocol for the management of lipid disorders.


Administration Scope

Feature Guideline
Route of administration Oral ingestion only.
Dosing schedule Starting Dose: 10 mg or 20 mg once daily. Maximum Dose: 40 mg once daily.
Timing in relation to meals Can be taken with or without food at any time of day.
Preparation requirements The tablet must be swallowed whole.

Instruction Classifications

Classification Detail
Administration method type Oral
Frequency pattern Once daily
Use-context constraints Must be used in conjunction with a standard cholesterol-lowering diet.

Resulting Procedural Structure and Adjustments

Official use involves initiating therapy at the appropriate labeled dose, with the flexibility to take the tablet with or without food. Dosage is reviewed and adjusted (titrated) as early as 2 to 4 weeks after initiation or dose change, based on the patient's individual response to therapy.

  • Population-Specific Starts: A lower starting dose (5 mg) is required for patients with severe renal impairment (who should not exceed 10 mg) and is advised for Asian patients. Older adults (>70 years) are also recommended to start at 5 mg.
  • Special Timing: If co-administering aluminum/magnesium hydroxide antacids, Rosuvastatin must be taken at least 2 hours before the antacid.
  • Missed Dose Rule: If a dose is missed, do not take an extra dose; simply continue with the next scheduled dose.

Connection to the Overall Use Protocol

The official instructions establish a structured, long-term protocol defined by a once-daily oral schedule, which is initiated and then adjusted over several weeks to meet therapeutic goals. This framework defines the dosage ranges, frequency, and specific intake rules, ensuring consistency with clinical standards.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Сувардио

This section provides a transparent overview of the research and studies conducted on Rosuvastatin, the active component in Сувардио. We summarize the types of trials performed, the outcomes that were monitored, and what areas of research remain uncertain. This information reflects group patterns observed in research and does not determine whether an individual person will experience a similar outcome.


Evidence for Managing High Cholesterol and Mixed Dyslipidemia

Researchers have conducted numerous Randomized Controlled Trials (RCTs) to explore the use of Rosuvastatin in adults diagnosed with primary hypercholesterolemia or mixed dyslipidemia. These studies focused primarily on biomarker shifts, which are measurements of certain substances in the body. The main outcomes examined were the changes in Low-Density Lipoprotein Cholesterol (LDL-C), Total Cholesterol, Triglycerides, and High-Density Lipoprotein Cholesterol (HDL-C). Studies reported measurements of lipid biomarkers across the populations examined over the study period. However, since the follow-up durations were often limited (sometimes just a few months), these findings provide context on blood fat changes, but the research does not establish the long-term clinical outcomes like heart attack or stroke for this specific group.


Evidence for Reducing Risk of Major Cardiovascular Events

Studies have also explored the use of Rosuvastatin in individuals who are at a high risk for cardiovascular disease but have not yet experienced a major event. This research used large-scale, long-term Randomized Controlled Trials (RCTs) to examine clinical events. The outcomes studied were primarily a composite endpoint of Major Adverse Cardiovascular Events (MACE), which includes non-fatal myocardial infarction (heart attack), non-fatal stroke, and cardiovascular death. Research also examined the inflammatory marker high-sensitivity C-Reactive Protein (hsCRP). Findings describe the measured event rates observed in these specific high-risk populations over the trial period.


What Remains Unclear or Unstudied About Сувардио’s Research

  • Long-term outcomes are not fully established across all indications; specifically, data that tracks the durability of lipid-level changes beyond a few years is limited in many of the initial comparative trials.
  • Findings relying solely on imaging or biomarker shifts (like LDL-C changes) are considered surrogate markers; research exploring the long-term clinical relevance of these short-term measurements is ongoing.
  • Subgroup findings related to specific genetic variations, such as the severe homozygous form (HoFH), or certain other comorbid conditions are often based on smaller patient populations or are still being explored, and data for these groups remains insufficient.

Key Studies & References

  1. Rosuvastatin: MedlinePlus Drug Information
  2. HMG-CoA Reductase Inhibitors (Statins) - NIH StatPearls

Frequently Asked Questions (FAQ)

Common questions about Сувардио (FAQ)

Q: How is Сувардио different from common treatments for the same condition?

A: Official classification documents describe the active ingredient in Сувардио (Rosuvastatin) as a hydrophilic statin. This scientific distinction relates to the drug’s high selectivity for the liver, known as hepatoselectivity, compared to some other medicines in the same class. This difference in targeting is a key feature that defines its pharmacological profile according to regulatory information.

Q: Does Сувардио interact with common vitamins or supplements?

A: Regulatory sources note that Rosuvastatin is known to interact with certain high-dose vitamins and herbal supplements. Specifically, supplements like Niacin (Vitamin B3) and the herbal supplement St. John's Wort are cited as potential interactions. Disclosing all supplements taken helps the prescribing physician check for potential interactions.

Q: Do people need special monitoring while taking Сувардио?

A: According to official product information, monitoring is required while taking this medicine. This typically involves blood tests, such as liver function tests, lipid panels, and sometimes Creatine Kinase (CK) levels. These checks are usually performed to gather information on the patient's response and to monitor potential effects on the body.

Q: Are there foods I need to avoid while on Сувардио?

A: Rosuvastatin can be taken either with or without food, as defined by the regulatory administration guidelines. Official regulatory documents indicate that Rosuvastatin is not known to interact with grapefruit or grapefruit juice. While the medicine should be used alongside a cholesterol-lowering diet, no specific food restrictions beyond this are typically listed in the product labeling.

Q: What if I'm allergic to other medications; can I still take Сувардио?

A: The official labeling states that use is contraindicated if there is a known hypersensitivity or allergy to the active ingredient or any of its components. The disclosure of all past and current drug allergies helps the healthcare provider evaluate eligibility for the medicine.

Q: Can Сувардио be taken by people with other chronic health problems?

A: The official labeling requires caution or dose adjustment for patients with specific health concerns, such as severe kidney impairment or pre-existing conditions that affect muscle function. Furthermore, the medicine is contraindicated in patients with active liver disease. These restrictions are documented requirements for aligning the drug's use with its approved safety profile.

Q: How long does it usually take for Сувардио to start working?

A: Studies indicate that the medicine begins to work in the body quickly. However, the maximum intended effect on lowering LDL-C (Low-Density Lipoprotein Cholesterol) is generally achieved within four weeks of starting treatment or following any subsequent dose change. The long-term therapeutic protocol relies on consistent use.

Q: What happens if I stop taking Сувардио suddenly?

A: Official regulatory patient information states that unauthorized, abrupt cessation of the medication should be avoided. Suddenly stopping Rosuvastatin may cause previously controlled cholesterol levels to rise again. The overall treatment protocol is structured for consistent use.

Q: Can Сувардио affect my sleep?

A: Official adverse reaction reporting documents list insomnia (difficulty sleeping) as an adverse reaction in the post-marketing experience for Rosuvastatin. While this effect is part of the overall safety profile, it is typically categorized as uncommon or rare in regulatory documentation.

Q: Does Сувардио affect the results of common lab tests?

A: Official product information notes that Rosuvastatin has been associated with changes in certain laboratory values. These include elevations in Creatine Kinase (CK) and liver enzymes, and changes in blood sugar (glucose) and protein in the urine. These values are part of the monitoring required while taking the medicine.

Q: Can Сувардио be taken with blood pressure medication?

A: Rosuvastatin does not have a general contraindication with the entire class of blood pressure medications. However, the product labeling emphasizes the importance of reviewing all medicines being taken. All current or new medications should be disclosed to the healthcare provider to check for specific interactions.

Q: Why is it important to take Сувардио exactly as prescribed?

A: Taking this medicine exactly as prescribed is the method defined in the label to achieve and maintain target cholesterol levels. Official patient information notes that stopping or changing the dose without medical advice may cause cholesterol levels to rise. Adherence is an essential element of the official management plan.

Q: Can Сувардио be taken with herbal remedies?

A: Regulatory and authoritative sources indicate that certain herbal remedies are known to interact with Rosuvastatin. Specifically, products like Red Yeast Rice and St. John's Wort can affect the drug's safety or effectiveness profile. The disclosure of all herbal remedy use helps the prescribing physician assess risk.

Q: Can Сувардио be taken with diabetes medication?

A: Rosuvastatin use has been associated with increases in blood sugar (glucose) and HbA1c levels in some patients. Patients who are also taking medication for diabetes may require closer blood sugar monitoring, which is a point of caution noted in the official regulatory documents.

Q: What does 'contraindication' mean regarding Сувардио?

A: A contraindication is a term used in official regulatory documents to describe a condition or situation where the risk of using a medicine significantly outweighs the therapeutic benefit. When a medicine is contraindicated, it signifies a mandatory exclusion from use in those specific circumstances as mandated by the regulatory label.

Q: Does Сувардио contain lactose or gluten?

A: The inactive ingredients (excipients) in most tablet formulations of Rosuvastatin include lactose monohydrate. However, the tablets are generally formulated to not contain gluten. The full list of inactive ingredients can be verified with a pharmacist to confirm alignment with dietary restrictions.

How should Сувардио be stored and disposed of?

Official Storage and Disposal Requirements

Rosuvastatin tablets (Сувардио) must be stored under specific environmental conditions to maintain stability, as required by regulatory labeling.

Storage & Disposal Element Official Regulatory Requirement
Storage Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted temporary excursions 15 C to 30 C (59 F to 86 F).
Protection Requirements Must be protected from moisture and stored away from excess heat.
Container Rules Keep the medicine in its original container with the container tightly closed.
Child-Safety Storage Must be stored out of the sight and reach of children.
Disposal Instructions Dispose of unused or expired product according to local requirements and generally avoid disposal in wastewater or household trash.

These official statements define the required temperature range and the need for protection from environmental factors like moisture and heat. The labeling mandates secure, out-of-reach storage from children and requires adherence to local guidelines for proper pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Сувардио found in:

A-Z Index: